Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. (NCT06236724)

🧪 Interventions in This Study

• Asciminib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• MD Anderson Cancer Center — Houston, Texas

📞 Contact the Study Coordinator

Phone: (713) 792-4764

Email: ejabbour@mdanderson.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Myeloid Leukemia

• Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population — Houston, Texas
• Selumetinib and Azacitidine in High Risk Chronic Blood Cancers — Chicago, Illinois
• A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia — New York, New York
• Study of Olverembatinib (HQP1351) in Patients With CP-CML — Houston, Texas
• Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase — Houston, Texas

Explore by condition: All Chronic Myeloid Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.